The Association of the British Pharmaceutical Industry (ABPI) have responded to today’s speech on the future of the UK’s relationship with the European Union (EU) by UK Prime Minister Theresa May at Santa Maria Novella, Florence, Italy.
Following the speech, The ABPI's Chief Executive Mike Thompson commented:
"We hope that today's intervention delivers sufficient progress to start negotiations about issues at stake for our sector and move everyone on to thinking about how we ensure Britain has a smooth and orderly exit from the EU.
The Prime Minister's speech is a welcome recognition of the importance of allowing reasonable time for industries like ours to plan and manage complicated changes in our supply chain and regulatory arrangements so that for patients across Europe, Brexit does not mean a break in their treatments.
The Life Sciences sector needs not only sufficient time to reorganise our work, but also sufficient clarity about our new trading and working relationship. We need a clearly defined goal to move to in one single step in order to avoid unnecessary delay and duplication.
Cooperation and alignment between the UK and the EU underpins many of the achievements that our industry continues to deliver for patients across Europe. We should not let the UK's withdrawal from the EU disrupt this work."
## ENDS ##
More information on the ABPI's work on Brexit is available here.
ABPI Press OfficeEmail: email@example.comTelephone (24hrs): +44 (0) 20 7747 7147
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.